         |
|
|
|
|
|
|
|||
Abbott
Drops Zomaxx; Immediately Starts Marketing of Xience Drug Eluting Stent |
|||
| October 6, 2006 -- Abbott, which acquired the Guidant-developed Xience stent as part of its deal with Boston Scientific, announced on Tuesday that it will immediately begin marketing the stent in Europe. Moreover, in a surprise to many observers, Abbott has cancelled its own drug-eluting stent, the Zomaxx, which was in clinical trials but not yet approved. The Zomaxx used Abbott's own zotarolimus drug, ABT-578, making it the only drug-eluting stent where both the device and the drug were going to be manufactured by the same company. The polymer which contained the drug was licensed from UK-based Biocompatibles International whose stock dropped 30% on the news. The Xience will also be marketed by Boston Scientific as the PROMUS drug-eluting stent. The marketing of these new stents begins to put them into competition in Europe with the current market leaders, Boston Scientific's Taxus and Johnson & Johnson / Cordis' Cypher stent, as well as Medtronics' Endeavor, which interestingly enough uses Abbott's ABT-578, the same drug used on the cancelled Zomaxx.
|
|||
Angioplasty.Org Home • PatientCenter send comments & suggestions
to "info at angioplasty dot org" |
|||